➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Harvard Business School
Merck
McKesson
Johnson and Johnson

Last Updated: June 19, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for VTP-27999


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug VTP-27999?

VTP-27999 is an investigational drug.

There have been 18 clinical trials for VTP-27999. The most recent clinical trial was a Phase 3 trial, which was initiated on January 21st 2019.

The most common disease conditions in clinical trials are Prostatic Neoplasms, Psoriasis, and Carcinoma, Transitional Cell. The leading clinical trial sponsors are Steba Biotech S.A., Vitae Pharmaceuticals, Inc., and STEBA France.

There are four US patents protecting this investigational drug and fifty-nine international patents.

Recent Clinical Trials for VTP-27999
TitleSponsorPhase
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) StudyMedpace, Inc.Phase 3
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) StudyPrimeVigilancePhase 3
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) StudySteba Biotech S.A.Phase 3

See all VTP-27999 clinical trials

Clinical Trial Summary for VTP-27999

Top disease conditions for VTP-27999
Top clinical trial sponsors for VTP-27999

See all VTP-27999 clinical trials

US Patents for VTP-27999

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
VTP-27999   Get Started Free Piperidine renin inhibitors Vitae Pharmaceuticals, Inc. (Fort Washington, PA)   Get Started Free
VTP-27999   Get Started Free Salts of methyl 2-((R)-(3-chlorophenyl)((R)-1-((S)-2-(methylamino)-3-((R)-tetrahydro-2H-p- yran-3-yl)propylcarbamoyl)piperidin-3-yl)methoxy)ethylcarbamate Vitae Pharmaceuticals, Inc. (Fort Washington, PA)   Get Started Free
VTP-27999   Get Started Free Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors Vitae Pharmaceuticals, Inc. (Fort Washington, PA)   Get Started Free
VTP-27999   Get Started Free Piperidine renin inhibitors Vitae Pharmaceuticals, Inc. (Fort Washington, PA)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for VTP-27999

Drugname Country Document Number Estimated Expiration Related US Patent
VTP-27999 Argentina AR057890 2025-11-14   Get Started Free
VTP-27999 Argentina AR062797 2025-11-14   Get Started Free
VTP-27999 Austria AT520690 2025-11-14   Get Started Free
VTP-27999 Austria AT538092 2025-11-14   Get Started Free
VTP-27999 Australia AU2006325322 2025-11-14   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Colorcon
Medtronic
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.